UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 410, 2026

Citius Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-41534		99-4362660
(Commission File Number)		(IRS Employer Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ		07016
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CTOR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 410, 2026, we issued a press release ~~announced~~ announcing positive topline ~~safety and efficacy~~ results from ana ~~investigator~~completed investigator-initiated Phase  1 clinical trial ~~evaluating~~conducted ~~LYMPHIR™~~by University of Pittsburgh investigators. This study evaluated the direct T-regulatory (~~E7777,~~Treg) cell depletion activity of LYMPHIR™ (denileukin diftitox -cxdl) ~~administered~~in ~~prior~~combination with tothe ~~commercial~~PD-1 ~~CD19~~immune ~~directed~~checkpoint ~~CAR~~inhibitor Tpembrolizumab ~~therapy~~(KEYTRUDA®) in patients with ~~high~~recurrent ~~risk~~or ~~relapsed~~refractory orgynecologic ~~refractory~~cancers, ~~diffuse~~including ~~large~~ovarian Band ~~cell~~endometrial ~~lymphoma (DLBCL)~~malignancies. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated March 410, 2026.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CITIUS ONCOLOGY, INC.
Date: March 4, 2026	/s/ Leonard Mazur
Date: March 10, 2026	/s/ Leonard Mazur
	Leonard Mazur
	Chairman and Chief Executive Officer

Filing Compare · CITIUS ONCOLOGY, INC.